Home Stocks PBYI Puma Biotechnology Inc (NASDAQ: PBYI) Healthcare · Biotechnology
— —
Quote unavailable · Price data is temporarily unavailable.
The Quantellect read. The borrow fee is 0.41%. One active firm covers the stock as of Nov 19, 2026; one active firm with a target averages $6.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.
Relative valuation Lower multiples than peers P/S 2.3× vs peer median 13.9×
Momentum Neutral RSI (14) 30.3 (overbought above 70, oversold below 30)
Short interest 10.6% of float FINRA settlement Oct 30, 2026
PBYI price chart Price — · As of —
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open —
Previous close —
Day range —
52-week range —
Volume —
Average volume (30 calendar days) —
Market cap —
P/E (TTM) —
Forward P/E —
EPS (TTM) —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) —
Price history PBYI · NASDAQ · USD
Split-adjusted · volume in shares
Price history unavailable Retry
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
How PBYI compares with its industry Against 592 other US-listed Biotechnology stocks
Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%
Strongest pointsTrailing-year return on equity was 22%, higher than 95% of 554 peers.Peer median −68.0% · As of Nov 17, 2026 Trailing-year net margin was 11.6%, higher than 94% of 583 peers.Peer median 0.0% · As of Nov 17, 2026 One-year return was 45.6%, higher than 83% of 522 peers.Peer median −28.4% · As of Nov 17, 2026 Points of cautionOne-month return was -32.9%, with only 21% of 567 peers reporting a lower value.Peer median −13.8% · As of Nov 17, 2026 Valuation Lower multiples than peers
Metric PBYI Peer median
Profitability Profitability metrics are higher than most peers.
Metric PBYI Peer median
Gross margin 74.8% 78.6%
Not ranked: only 246 of 592 peers report it
Operating margin 13.4% 0.0%
Top 10% of peers Higher than 90% of 442 peers
Net margin 11.6% 0.0%
Top 10% of peers Higher than 94% of 583 peers
Return on equity 22.0% −68.0%
Top 10% of peers Higher than 95% of 554 peers
Growth Growth metrics are higher than most peers.
Metric PBYI Peer median
Quarterly sales growth, year over year 7.8% 0.0%
Higher than 72% of 592 peers
5-year sales growth rate 0.3% 11.6%
Not ranked: only 139 of 592 peers report it
Balance sheet Balance sheet metrics are lower than most peers.
Metric PBYI Peer median
Momentum Returns are higher than most peers.
Metric PBYI Peer median
1-year return +45.6% −28.4%
Higher than 83% of 522 peers
6-month return +3.3% −26.7%
Higher than 73% of 545 peers
3-month return −20.7% −29.9%
Higher than 64% of 558 peers
How to read this The dot marks where PBYI ranks among its peers on each metric, from lowest (left) to highest (right). The tick in the middle marks the peer median.
Green marks a rank in the top 10% of peers, amber the bottom 10%. Valuation and balance-sheet metrics stay neutral because a high rank there is not better or worse.
A metric is ranked only when enough peers report it. Peers exclude this company. Percentages count peers with a strictly lower value; equal values do not count.
Lowest Median Highest
Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 13, 2026
Upcoming events — · Upcoming events not available
Analyst consensus Insufficient coverage
0 Strong Buy
0 Buy
1 Neutral
0 Sell
0 Strong Sell
Based on 1 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $6.00
Average $6.00
High $6.00
As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −0.20 0.00 0.20 0.40 0.60 0.80 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 $0.06 $0.11 —
Q2 2026 — $0.16 —
Q1 2026 −$0.13 −$0.07 —
Annual 2025 — $0.61 —
Q3 2025 — $0.17 —
Q2 2025 — $0.12 —
Q1 2025 — $0.06 —
Annual 2024 $0.14 $0.62 —
Smart-money activity In the last 60 days: 1 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
Date Type Who Action Amount Source
Nov 11, 2026 Insider sell MILLER MICHAEL PATRICK Sell $121.5K Form 4 Sep 14, 2026 Insider sell WILSON TROY EDWARD Sell $45.5K Form 4 Sep 14, 2026 Insider sell Cesano Alessandra Sell $567.0K Form 4 Jul 6, 2026 Insider sell AUERBACH ALAN H Sell $364.1K Form 4 Jul 6, 2026 Insider sell HUNT DOUGLAS M Sell $69.9K Form 4 Jul 6, 2026 Insider sell NOUGUES MAXIMO F Sell $77.6K Form 4 Jun 12, 2026 Insider sell WILSON TROY EDWARD Sell $77.7K Form 4 Jun 12, 2026 Insider sell Stuglik Brian M Sell $58.3K Form 4 Jun 12, 2026 Insider sell Senderowicz Adrian Sell $194.3K Form 4 Jun 12, 2026 Insider sell MOYES JAY M Sell $158.8K Form 4 All smart-money activity →
News and press releases Year All 2026 Nov 5, 2026, 4:05 PM ET Oct 22, 2026, 4:11 PM ET All PBYI news → Company profile Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A
CEO Mr. Alan H. Auerbach
Headquarters Los Angeles, CA, United States
Employees 179
IPO date Apr 24, 2012
Sector Healthcare
Industry Biotechnology Q Score — · Q Score not available
Upcoming events — · Upcoming events not available
Analyst consensus Insufficient coverage
0 Strong Buy
0 Buy
1 Neutral
0 Sell
0 Strong Sell
Based on 1 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $6.00
Average $6.00
High $6.00
As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −0.20 0.00 0.20 0.40 0.60 0.80 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 $0.06 $0.11 —
Q2 2026 — $0.16 —
Q1 2026 −$0.13 −$0.07 —
Annual 2025 — $0.61 —
Q3 2025 — $0.17 —
Q2 2025 — $0.12 —
Q1 2025 — $0.06 —
Annual 2024 $0.14 $0.62 —
Company profile Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A
CEO Mr. Alan H. Auerbach
Headquarters Los Angeles, CA, United States
Employees 179
IPO date Apr 24, 2012
Sector Healthcare
Industry Biotechnology